Döhner, H., Weber, D., Krzykalla, J., Fiedler, W., Kühn, M. W. M., Schroeder, T., . . . Ganser, A. (2023). Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): A randomised, open-label, multicentre, phase 3 trial. The lancet. Haematology, 10(7), . https://doi.org/10.1016/S2352-3026(23)00089-3
Chicago-Zitierstil (17. Ausg.)Döhner, Hartmut, et al. "Intensive Chemotherapy with or Without Gemtuzumab Ozogamicin in Patients with NPM1-mutated Acute Myeloid Leukaemia (AMLSG 09-09): A Randomised, Open-label, Multicentre, Phase 3 Trial." The Lancet. Haematology 10, no. 7 (2023). https://doi.org/10.1016/S2352-3026(23)00089-3.
MLA-Zitierstil (9. Ausg.)Döhner, Hartmut, et al. "Intensive Chemotherapy with or Without Gemtuzumab Ozogamicin in Patients with NPM1-mutated Acute Myeloid Leukaemia (AMLSG 09-09): A Randomised, Open-label, Multicentre, Phase 3 Trial." The Lancet. Haematology, vol. 10, no. 7, 2023, https://doi.org/10.1016/S2352-3026(23)00089-3.